Differences in nephrotoxicity risk and renal effects among anti‐viral therapies against hepatitis B

Abstract

Although tenofovir caused a decline in GFR, differences between the anti-viral agents do not appear to be so impressive. In patients with and without renal risk factors at baseline, there is no impact of anti-virals, including tenofovir.